Oridonin induces apoptosis in HGC‑27 cells by activating the JNK signaling pathway

Abstract

Gastric cancer (GC) is a very common type of cancer. Although current treatment modalities include surgical resection and chemotherapy, many patients are either not eligible for radical resection or have a poor response to chemotherapy. Due to the complex features of the disease, there is a need for complementary therapy. In the present study, the effects of oridonin on cell proliferation, invasion and apoptosis were assessed in the HGC-27 cell line using the Cell Counting Kit-8 assay, real-time cell analysis, and an Annexin V-FITC/propidium iodide (PI) detection kit, respectively. The effect of oridonin on apoptosis, through the JNK pathway, was also investigated using western blotting. The present study demonstrated that oridonin can suppress cell viability and inhibit cell proliferation by inducing G2/M arrest. Oridonin also induced caspase-dependent apoptosis in cells by activating the phosphorylated-JNK/C-JUN pathway. These results demonstrate the potential of oridonin as a potential therapeutic compound for the treatment of GC.

Oridonin Induces Apoptosis in Esophageal Squamous Cell Carcinoma by Inhibiting Cytoskeletal Protein LASP1 and PDLIM1

“…On t(8;21) acute leukemia myeloid, oridonin induced apoptosis and targets the important AML1-ETO fusion protein in leukemogenesis [ 24 ]. Oridonin also acts with several critical signaling pathways such as AKT [ 25 ], Ras/Raf [ 26 ], JNK [ 27 ], and NLRP3 [ 28 ]. At present, using proteomics including 2D SDS-PAGE and chemical proteomics, six articles pointed out 24 impacted proteins that were conducted as the gene pool in the current study [ 15 , 16 , 17 , 18 , 19 , 20 ].…”

Key Targets and Molecular Mechanisms of Active Volatile Components of Rabdosia rubescens in Gastric Cancer Cells

“…R. rubescens not only greatly improves the anti-tumor effect of chemotherapy drugs but also reduces the required dosage and side effects [ 10 , 11 ]. R. rubescens contains a large amount of volatile oil, mostly monoterpenes and long-chain hydrocarbons, including α-pinene and β-pinene, limonene, 1,8-eucalyptusp-paragenin, nonanal, decanal, β-elemene, palmitic acid, tridecane, and squalene [ 12 ]. Limonene, α-pinene, β-pinene, β-elemene, and other volatile components have anti-tumor effects [ 13 , 14 ].…”

Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells

“…Donglingcao is a commonly available over-thecounter (OTC) herbal medicine for the treatment of inflammation and cancer in China [32][33][34]. Oridonin, as one of the main active components of Donglingcao, exhibits a promising safety profile and potent antitumor activities [11][12][13][14][15][16][17][18][19][20]. In view of its good stability, large commercially available supply, and suitable molecular weight, oridonin is a potential anticancer drug candidate.…”

“…Oridonin, from the Chinese herb Rabdosia rubescens, is a kaurene diterpenoid (Figure 1(a)) that exhibits activity against pancreatic, breast, prostate, and lung cancers and leukemia [11][12][13][14][15][16]. Oridonin activates apoptosis, cell senescence, and autophagy by modulating the PI3K/AKT, JNK, Wnt/β-catenin, TGF-β1/ Smads-PAI-1, mTOR, and Notch signaling pathways [15][16][17][18][19][20]. However, the low oral bioavailability (less than 5%) and imprecise mechanisms of oridonin have greatly impacted its potential clinical implications [21].…”